Clinical Trial Update: Continuous Infusion of Ropivacaine Hydrochloride in Reducing Pain After Surgery in Patients With Bladder Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating continuous infusion of ropivacaine hydrochloride to reduce postoperative pain after bladder cancer surgery was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Postoperative Pain

Drugs mentioned

• Ropivacaine hydrochloride (ropivacaine hydrochloride)

Snippet

Sponsor: University of Southern California | Conditions: Bladder Carcinoma, Post-operative Pain | Phase 3 | Status: WITHDRAWN